Best Peptides for Fatigue & Low Energy: What the Clinical Evidence Actually Shows

Elamipretide ranks first because it is the only peptide here ever measured against validated fatigue scales in randomized controlled trials — so for the question 'does a peptide reduce fatigue in humans,' this is the closest thing to a real answer, and the answer is sobering. In the small Phase 2 crossover trial (MMPOWER-2) in primary mitochondrial myopathy, participants reported a 1.7-point relative reduction on the four-question PMMSA Total Fatigue score versus placebo (95% CI -2.6 to -0.8; P=0.0006) plus reduced fatigue-during-activities (P=0.0018). But the definitive Phase 3 MMPOWER-3 trial (N=218, 24 weeks) then failed the very same endpoint — the between-group PMMSA Total Fatigue difference was -0.07 (95% CI -0.10 to 0.26; P=0.37) — alongside a null six-minute-walk result (P=0.69). In Barth syndrome, the randomized phase of TAZPOWER likewise did not meet its primary endpoints, which included the BTHS-SA fatigue assessment; a pre-specified nuclear-DNA subgroup improved, motivating the ongoing NuPOWER trial. Its sole FDA approval (Forzinity, September 2025) is for Barth syndrome, not fatigue, and there is no evidence for it in idiopathic, everyday or age-related fatigue. Elamipretide binds cardiolipin to stabilize cristae and the oxidative-phosphorylation supercomplexes; notably, 'fatigue' itself was a reported adverse event in the program — it is not a clean stimulant. A positive small-trial signal that did not replicate: Grade B, mixed-to-negative for fatigue.

Best for

Understanding why the mitochondrial rationale, even at its strongest, has not delivered a reliable fatigue benefit

Pricing

Prescription (Forzinity, Barth syndrome only) / no fatigue pathway

Source: Karaa et al., MMPOWER-3, Neurology 2023 (PMC10382259)

Thymosin alpha-1 ranks second because it has the strongest and deepest human evidence base of the five — it is an approved drug in 30-plus countries with RCTs and meta-analyses — and the one mechanism most relevant to a specific, common cause of chronic fatigue: post-viral immune dysregulation. But its fatigue relevance is inferred from immune data, not a positive fatigue trial. The most fatigue-adjacent evidence comes from post-viral immunology: in a retrospective severe-COVID cohort, Tα1 was associated with reduced mortality and reversal of T-cell exhaustion (PD-1/Tim-3) in lymphopenic patients, and in an ex vivo PASC study it reduced exhausted CD4/CD8 T cells and raised IL-10, with the largest effect in patients who had systemic symptoms including asthenia. Crucially, in that study fatigue was a stratifying variable, not a measured clinical endpoint, and no patient was treated. Its robust RCT/meta-analytic evidence is in chronic hepatitis B (pooled OR around 2.67), and — importantly for honesty — its highest-quality trial, TESTS in sepsis (N=1,089), was negative (HR 0.99), showing the peptide does not uniformly deliver on its immune promise. A widely repeated vendor claim of a positive long-COVID fatigue RCT ('72% vs 23%') could not be verified in any indexed primary source and should be treated as unsubstantiated. Tα1 is unusually well tolerated (under 1% drug-related adverse events), but caution applies in deliberate immunosuppression, and the sepsis trial's exploratory signal of possible higher mortality in younger patients (HR 1.67) is a reminder that immune modulation is context-dependent. A biologically plausible tool for the immune layer of post-viral fatigue, unproven as a fatigue treatment: Grade B for immunity, indirect for fatigue.

Best for

The immune-targeted rationale in post-viral or long-COVID fatigue, understood as a hypothesis rather than an evidenced therapy

Pricing

Prescription abroad (Zadaxin) / US compounding gray zone; varies by pharmacy

Source: Pham et al., Clin Immunol 2023 (PMC10030336)

MOTS-c ranks third because it has the most compelling biological story for fatigue — a mitochondrial-DNA-encoded 'exercise mimetic' that activates AMPK, drives GLUT4-mediated glucose uptake and fat oxidation, and is explicitly discussed as a candidate for the mitochondrial and glycolytic impairment seen in ME/CFS — but every efficacy claim is animal or in vitro, with zero completed human efficacy trials. The animal evidence is genuinely striking: intermittent MOTS-c improved physical performance across the lifespan in mice, and late-life treatment roughly doubled treadmill running capacity in old mice while improving healthspan; it also prevents diet-induced obesity and improves insulin sensitivity in rodents. The human evidence, however, is only observational biomarker data: circulating MOTS-c declines with age and tracks lower in diabetes and obesity, while exercise raises endogenous MOTS-c around 12-fold in muscle — establishing it as an exercise-responsive peptide, not proof that injecting it helps. The mitochondrial and glycolytic deficits documented in ME/CFS are the stated rationale for evaluating mitochondrial-derived peptides in that population, but that is rationale, not result. The first human RCT (Phase 2a, NCT07505745) — in prediabetes/obesity, with insulin sensitivity, not fatigue, as the endpoint — only began recruiting in February 2026, with no results. Rodent studies use intraperitoneal injection; there is no validated human dose or pharmacokinetics, and online 'research' dosing (around 5–10 mg SC weekly) is unverified. Safety is uncharacterized: no controlled human data exist, uncontrolled user reports include palpitations, elevated heart rate, insomnia and fever — the opposite of restful energy — and MOTS-c has been banned by WADA as an AMPK activator since 2024. The honest reading is the reverse of the hype: MOTS-c is a marker of the benefits of actual exercise. Grade C, preclinical only.

Best for

Recognizing where the evidence is most preclinical — dramatic rodent biology and biomarkers, not human treatment

Pricing

No approved product; 'research-use-only' material is unapproved/unverified

Source: Reynolds et al., Nat Commun 2021

CJC-1295 without DAC ranks fourth: it is a real GHRH-receptor agonist with sound pharmacology — it triggers a growth-hormone pulse — and it is heavily marketed, usually stacked with ipamorelin, for 'energy, recovery and deep sleep.' But there is no human RCT of the molecule itself for anything, let alone fatigue. Its GH-release data come from rats and cell culture (Grade C). The human trials people cite belong to the different, long-acting DAC version, which produces a sustained GH and IGF-1 rise and was well tolerated short-term — but those data do not transfer as efficacy for the short-acting no-DAC product. The rationale offered is the somatotropic axis: endogenous GH is secreted in pulses tied to slow-wave sleep and declines with age ('somatopause'), and slow-wave sleep and GH are physiologically linked. The logic is biologically real; the outcome — less fatigue — is the part that has never been tested in a controlled fatigue or sleep trial of this peptide. The 'more energy, better sleep, faster recovery' claims are therefore mechanistic extrapolation and anecdote (Grade D). Anecdotal dosing cites around 100 µg SC pre-sleep, often co-injected with 100–300 µg ipamorelin, with no validated human regimen. On safety, reported effects include injection-site reactions, flushing, water retention and — tellingly — somnolence and drowsiness, meaning it can sedate rather than energize; there is also theoretical insulin resistance (which itself worsens fatigue) and IGF-1-mediated tumor/angiogenesis concern, plus immunogenicity and impurity risk from unregulated product. CJC-1295 is WADA-prohibited at all times. Sound pharmacology, no fatigue evidence: Grade C/D.

Best for

Seeing how a real GH-releasing mechanism gets marketed for 'energy' far ahead of any fatigue evidence

Pricing

No approved product; unregulated 'research' material

Source: Jetté et al., Endocrinology 2005 (PMID 15817669)

Ipamorelin ranks last because, like CJC-1295, it reliably releases growth hormone — a Grade B pharmacodynamic fact in humans — but its single human efficacy RCT, in a non-fatigue indication, failed, and no fatigue or energy trial has ever been done. Ipamorelin produces a clean, selective GH pulse in humans, well characterized in Phase 1 pharmacokinetic and pharmacodynamic work. However, its only published efficacy RCT (postoperative ileus, N around 114) missed its primary endpoint, and development in that indication was discontinued. Claims of improved energy, recovery, body composition or sleep are Grade C to D — animal, mechanistic or anecdotal — with no fatigue endpoint ever tested. It is popularly stacked with CJC-1295 for 'energy and recovery,' but no controlled trial of the stack exists either, and the GH pulse itself can cause drowsiness and reduce insulin sensitivity, both of which can lower rather than raise daytime energy. Trials used the intravenous route; community and compounded use cites subcutaneous 100–300 µg one to three times daily, which is unvalidated. On safety, ipamorelin is generally well tolerated in short trials, but the class effect of transient hyperglycemia and reduced insulin sensitivity applies, along with water retention, headache and a theoretical IGF-1-mediated proliferation risk; chronic and long-term subcutaneous safety is unstudied. Ipamorelin is WADA-prohibited at all times. A reliable GH secretagogue whose one efficacy test failed, with no fatigue evidence whatsoever: Grade C/D.

Best for

Understanding that reliable GH release is not the same as a proven fatigue or energy benefit

Pricing

No approved product; unregulated 'research' material

Source: Beck et al., Int J Colorectal Dis 2014 (PMID 25331030)